Autopsy report · NCT03517566

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

“Lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 year 9 months before it stopped.
• 293 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Atopic Dermatitis

Interventions

Placebo; ZPL389 3mg; ZPL389 10mg; ZPL389 30mg; ZPL389 50mg

Participants

293

Sites

89

Countries

Austria, Belgium, Canada, Czechia, Finland, Germany, Hungary, Iceland, Japan, Netherlands, Poland, Russia and more

Trials that died the same way

• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (91% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (85% match in meaning)
• Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
  “Lack of effectiveness” (81% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (77% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.